Verastem, Inc. (VSTM)

Last Price:  

Company Description

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $17.46M
Net Income (Most Recent Fiscal Year) $-149.21M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 11.70
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 1.93
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -715.40%
Net Margin (Trailing 12 Months) -715.40%
Return on Equity (Trailing 12 Months) -282.13%
Return on Assets (Trailing 12 Months) -74.19%
Current Ratio (Most Recent Fiscal Quarter) 5.78
Quick Ratio (Most Recent Fiscal Quarter) 5.61
Debt to Common Equity (Most Recent Fiscal Quarter) 0.48
Inventory Turnover (Trailing 12 Months) 1.53
Book Value per Share (Most Recent Fiscal Quarter) $0.09
Earnings per Share (Most Recent Fiscal Quarter) $-0.35
Earnings per Share (Most Recent Fiscal Year) $-2.00
Diluted Earnings per Share (Trailing 12 Months) $-1.84
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 162.53M
Free Float 157.82M
Market Capitalization $243.80M
Average Volume (Last 20 Days) 7.18M
Beta (Past 60 Months) 1.21
Percentage Held By Insiders (Latest Annual Proxy Report) 2.90%
Percentage Held By Institutions (Latest 13F Reports) 50.72%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%